| Q41218466 | A "vicious cycle" of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL? |
| Q36482032 | A CXCL1 paracrine network links cancer chemoresistance and metastasis |
| Q24338768 | A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1 |
| Q28306743 | A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4 |
| Q47643448 | A nonimmune function of T cells in promoting lung tumor progression |
| Q58700691 | A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2 |
| Q35626799 | A seven-gene CpG-island methylation panel predicts breast cancer progression |
| Q41564767 | A signal-based method for finding driver modules of breast cancer metastasis to the lung. |
| Q35659971 | Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors |
| Q37706111 | Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer |
| Q53070583 | Activation of AhR with nuclear IKKα regulates cancer stem-like properties in the occurrence of radioresistance. |
| Q37356654 | Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines |
| Q91754904 | Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression |
| Q37685867 | Amigo2-upregulation in Tumour Cells Facilitates Their Attachment to Liver Endothelial Cells Resulting in Liver Metastases. |
| Q38097243 | An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer |
| Q38075495 | Animal model for mammary tumor growth in the bone microenvironment |
| Q26796542 | Antibody-based immunotherapy of solid cancers: progress and possibilities |
| Q36922033 | Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity |
| Q36854682 | Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis |
| Q38045603 | Basic principles of tumor-associated regulatory T cell biology |
| Q28265584 | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab |
| Q34366449 | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond |
| Q36537204 | Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients |
| Q92253913 | Bone Metastasis: Current State of Play |
| Q27022883 | Bone specific immunity and its impact on metastasis |
| Q28087676 | Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? |
| Q36653524 | Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade |
| Q37973821 | Breast-cancer stem cells-beyond semantics |
| Q34657809 | C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation |
| Q37295330 | CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells |
| Q35214342 | CD105 expression on CD34-negative spindle-shaped stromal cells of primary tumor is an unfavorable prognostic marker in early breast cancer patients |
| Q35968894 | CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment |
| Q58781616 | Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu |
| Q35598951 | Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation |
| Q91691166 | Cancer-associated fibroblasts in gastrointestinal cancer |
| Q92963134 | Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy |
| Q84744532 | Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance |
| Q37061749 | Carcinoma-associated fibroblasts are a promising therapeutic target. |
| Q90278559 | Caveolin‑1 enhances RANKL‑induced gastric cancer cell migration |
| Q39014552 | Cell lineage determinants as regulators of breast cancer metastasis |
| Q37078475 | Chemokines and chemokine receptors as promoters of prostate cancer growth and progression |
| Q90401357 | Chemokines in Physiological and Pathological Bone Remodeling |
| Q38682103 | Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort |
| Q53732017 | Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. |
| Q39036670 | Clinical significance of CYLD downregulation in breast cancer |
| Q91651961 | Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas |
| Q36075768 | Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria |
| Q34201118 | Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells |
| Q35624809 | Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer. |
| Q42571627 | Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer |
| Q37986124 | Denosumab for treatment of breast cancer bone metastases and beyond |
| Q37974570 | Denosumab in patients with cancer-a surgical strike against the osteoclast |
| Q36450727 | Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer |
| Q58762354 | Distribution and prognostic value of tumor‑infiltrating T cells in breast cancer |
| Q38955517 | Drugs in early clinical development for the treatment of osteosarcoma |
| Q48193895 | Dynamics of regulatory T cells (Tregs ) in patients with oral squamous cell carcinoma. |
| Q36698273 | Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. |
| Q37441693 | Effects of RANKL-Targeted Therapy in Immunity and Cancer |
| Q55077356 | Emerging Functions of Regulatory T Cells in Tissue Homeostasis. |
| Q35686250 | Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. |
| Q38264092 | Emerging roles of regulatory T cells in tumour progression and metastasis |
| Q38008496 | Emerging roles of the tumor-associated stroma in promoting tumor metastasis. |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q38341899 | Endocrine hormones and local signals during the development of the mouse mammary gland. |
| Q89164779 | Engineering the pre-metastatic niche |
| Q57154016 | Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma |
| Q35014814 | Expression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients |
| Q91310928 | Fibroblasts Fuel Immune Escape in the Tumor Microenvironment |
| Q39984572 | Flesh-eating Streptococcus pyogenes triggers the expression of receptor activator of nuclear factor-κB ligand |
| Q59799443 | Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma |
| Q38045235 | From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation |
| Q35659426 | From the ranks of mammary progesterone mediators, RANKL takes the spotlight |
| Q38202990 | Functional dynamics of Foxp3⁺ regulatory T cells in mice and humans. |
| Q36076453 | Future perspectives of prostate cancer therapy |
| Q33652169 | GFI1 downregulation promotes inflammation-linked metastasis of colorectal cancer |
| Q26825120 | Galectin-1 research in T cell immunity: past, present and future |
| Q24568374 | Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression |
| Q38735527 | HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. |
| Q37476039 | Harnessing the immune system for the treatment of breast cancer |
| Q90442956 | Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond |
| Q33558230 | Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis |
| Q34598936 | Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells |
| Q38226179 | Hormonal regulation of the immune microenvironment in the mammary gland |
| Q53236646 | IKKα promotes intestinal tumorigenesis by limiting recruitment of M1-like polarized myeloid cells. |
| Q36924500 | Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration |
| Q37719488 | Immune Regulation of the Metastatic Process: Implications for Therapy |
| Q26991724 | Immune cell promotion of metastasis |
| Q35642044 | Immune microenvironments in solid tumors: new targets for therapy |
| Q36204083 | Immune modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid |
| Q27005871 | Immune regulation of bone metastasis |
| Q57791068 | Immune regulation of metastasis: mechanistic insights and therapeutic opportunities |
| Q38122647 | Immune system: a double-edged sword in cancer |
| Q36106053 | Immunity, inflammation, and cancer: an eternal fight between good and evil |
| Q38608340 | Immunological hallmarks of stromal cells in the tumour microenvironment |
| Q84066899 | Immunology: Pro-metastatic T(Reg)cells get RANKed |
| Q28083450 | Immunosuppression associated with chronic inflammation in the tumor microenvironment |
| Q38154151 | Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. |
| Q55257180 | Immunotherapeutic interventions of Triple Negative Breast Cancer. |
| Q28732675 | In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration |
| Q34974617 | In vivo imaging and histochemistry are combined in the cryosection labelling and intravital microscopy technique |
| Q84515527 | Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer |
| Q38769921 | Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals |
| Q38964798 | Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling |
| Q28396089 | Inflammation and skeletal metastasis |
| Q29620242 | Inflammation meets cancer, with NF-κB as the matchmaker |
| Q64099539 | Inhibition of NK Reactivity Against Solid Tumors by Platelet-Derived RANKL |
| Q34295493 | Inhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer |
| Q42578523 | Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature |
| Q36848283 | Interaction among cells of bone, immune system, and solid tumors leads to bone metastases |
| Q55313422 | Interplay of Viral Infection, Host Cell Factors and Tumor Microenvironment in the Pathogenesis of Nasopharyngeal Carcinoma. |
| Q36503942 | Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies |
| Q38019416 | Intratumoral stages of metastatic cells: a synthesis of ontogeny, Rho/Rac GTPases, epithelial-mesenchymal transitions, and more |
| Q54200830 | LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. |
| Q37317234 | LGR5 expression is controled by IKKα in basal cell carcinoma through activating STAT3 signaling pathway |
| Q52714204 | LW106, A Novel Inhibitor of IDO1, Suppresses Tumor Progression by Limiting Stroma-Immune Crosstalk and Cancer Stem Cell Enrichment in the Tumor Microenvironment. |
| Q36845822 | Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade |
| Q37987842 | Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity |
| Q34308847 | Lymphotoxin, NF-ĸB, and cancer: the dark side of cytokines |
| Q42182045 | MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness. |
| Q37078995 | Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs |
| Q38439266 | Mechanisms of aromatase inhibitor resistance. |
| Q35673417 | Mechanisms of cancer cell metastasis to the bone: a multistep process |
| Q44577463 | Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. |
| Q58724203 | Merkel cell polyomavirus and Langerhans cell neoplasm |
| Q38059338 | Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? |
| Q88693147 | Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy |
| Q92243276 | MiR-195 restrains lung adenocarcinoma by regulating CD4+ T cell activation via the CCDC88C/Wnt signaling pathway: a study based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and bioinformatic analysis |
| Q35157020 | MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease |
| Q87573906 | Molecular response of the axillary lymph node microenvironment to metastatic colonization |
| Q35063276 | Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region |
| Q38155200 | Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis |
| Q38359190 | NF-κB in cancer therapy. |
| Q26801253 | New and emerging factors in tumorigenesis: an overview |
| Q38052462 | New developments in osteoimmunology |
| Q97419539 | Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells |
| Q41135180 | OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer |
| Q37180457 | OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential. |
| Q37330542 | Obesity-associated NLRC4 inflammasome activation drives breast cancer progression |
| Q63565679 | Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4 |
| Q92052373 | Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice |
| Q36413217 | Opposed expression of IKKα: loss in keratinizing carcinomas and gain in non-keratinizing carcinomas |
| Q36480992 | Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss |
| Q97423686 | Osteoclast Signal Transduction During Bone Metastasis Formation |
| Q47712068 | Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis. |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q92668034 | Osteoimmunology: evolving concepts in bone-immune interactions in health and disease |
| Q47861377 | Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells. |
| Q36080689 | POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment |
| Q64244173 | PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185 Tumor Immunotherapy |
| Q35612391 | Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells |
| Q26777205 | Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate |
| Q52804185 | Phosphanegold(I) thiolates, Ph3PAu[SC(OR)=NC 6H 4Me-4] for R = Me, Et and iPr, induce apoptosis, cell cycle arrest and inhibit cell invasion of HT-29 colon cancer cells through modulation of the nuclear factor-κB activation pathway and ubiquitinatio |
| Q38857539 | Precancer Atlas to Drive Precision Prevention Trials. |
| Q38109029 | Progesterone signalling in breast cancer: a neglected hormone coming into the limelight |
| Q51042996 | Progesterone/RANKL is a major regulatory axis in the human breast. |
| Q27318199 | Prospects for therapeutic tolerance in humans |
| Q43142242 | Prospects of adjuvant RANKL inhibition in breast cancer? |
| Q36729107 | Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. |
| Q26830075 | Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads |
| Q36134061 | Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis |
| Q38691526 | RANK as a therapeutic target in cancer. |
| Q52877576 | RANK expression as a prognostic and predictive marker in breast cancer. |
| Q47106594 | RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target? |
| Q39055979 | RANK expression on breast cancer cells promotes skeletal metastasis |
| Q33895612 | RANK rs1805034 T>C polymorphism is associated with susceptibility of esophageal cancer in a Chinese population |
| Q37648868 | RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization |
| Q26747442 | RANK-RANKL signalling in cancer |
| Q88911025 | RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling |
| Q35218182 | RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy |
| Q40030944 | RANK/RANKL expression in prostate cancer |
| Q36491425 | RANK/RANKL pathway in cancer: Biological activity beyond bone? |
| Q37865171 | RANKL inhibition: a promising novel strategy for breast cancer treatment. |
| Q36253034 | RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers |
| Q37582762 | RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src |
| Q92612736 | RANKL/RANK promotes the migration of gastric cancer cells by interacting with EGFR |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q28075004 | RANKL/RANK: from bone loss to the prevention of breast cancer |
| Q49371326 | Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis |
| Q91253715 | Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma |
| Q38747404 | Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). |
| Q36180432 | Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification |
| Q26742012 | Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting |
| Q36018275 | Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners |
| Q26991447 | Regulatory T cell: a protection for tumour cells |
| Q33784969 | Regulatory T cells in multiple sclerosis and myasthenia gravis. |
| Q38139203 | Regulatory T cells in nonlymphoid tissues |
| Q57471979 | Regulatory T cells in the treatment of disease |
| Q36085081 | Regulatory T cells turn pathogenic |
| Q38202988 | Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation |
| Q34473935 | Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development |
| Q36342182 | Reproductive history and breast cancer risk. |
| Q35799094 | Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. |
| Q37679393 | Roadblocks to translational advances on metastasis research |
| Q37241255 | Role of RANKL/RANK in primary and secondary breast cancer |
| Q30455154 | Role of denosumab in prostate cancer |
| Q39914415 | Role of the nervous system in cancer metastasis. |
| Q38830072 | Roles of regulatory T cells in cancer immunity |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q34413441 | Roles of tumor suppressors in regulating tumor-associated inflammation |
| Q34100910 | SCFβ-TRCP regulates osteoclastogenesis via promoting CYLD ubiquitination |
| Q64951290 | Sclerotic Bone Metastasis in Pulmonary Adenocarcinoma. |
| Q39090351 | Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study |
| Q38581768 | Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. |
| Q37238831 | Specific recruitment of γδ regulatory T cells in human breast cancer. |
| Q38172858 | Stimuli-induced organ-specific injury enhancement of organotropic metastasis in a spatiotemporal regulation. |
| Q35130819 | Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 |
| Q38017601 | Stromal biomarkers in breast cancer development and progression |
| Q35609967 | Stromal cells in tumor microenvironment and breast cancer |
| Q50994600 | Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. |
| Q27311542 | T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer |
| Q47852200 | T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. |
| Q39399239 | Taming the immune system through transfusion in oncology patients |
| Q59329292 | Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors |
| Q26849690 | Targeting RANKL in metastasis |
| Q91565659 | Targeting Tumor Microenvironment by Small-Molecule Inhibitors |
| Q98166041 | Targeting regulatory T cells for improving cancer therapy: Challenges and prospects |
| Q27022348 | Targeting regulatory T cells in cancer |
| Q38703565 | Targeting regulatory T cells in tumors |
| Q98771227 | Targeting the RANKL/RANK/OPG Axis for Cancer Therapy |
| Q91688036 | Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy |
| Q64105357 | The Contribution of the Immune System in Bone Metastasis Pathogenesis |
| Q36356112 | The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. |
| Q93216958 | The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice |
| Q88723986 | The Immunobiology of Receptor Activator for Nuclear Factor Kappa B Ligand and Myeloid-Derived Suppressor Cell Activation in Immunoglobulin G4-Related Sclerosing Cholangitis |
| Q38524842 | The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors |
| Q57166654 | The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy |
| Q34066731 | The IκB kinase complex is required for plexin-B-mediated activation of RhoA |
| Q41200607 | The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. |
| Q64120685 | The Uncovered Role of Immune Cells and NK Cells in the Regulation of Bone Metastasis |
| Q53807792 | The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer. |
| Q38029394 | The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction |
| Q37976939 | The diverse and complex roles of NF-κB subunits in cancer |
| Q37474735 | The diverse roles of the TNF axis in cancer progression and metastasis |
| Q64934031 | The effects of epidural anaesthesia and analgesia on T lymphocytes differentiation markers and cytokines in patients after gastric cancer resection. |
| Q37033451 | The immune system and inflammation in breast cancer |
| Q26851314 | The microenvironment in breast cancer progression: biology and implications for treatment |
| Q35931795 | The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells |
| Q37520235 | The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. |
| Q49163652 | The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients |
| Q35531372 | The role of the cell-cell interactions in cancer progression |
| Q38922999 | The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas. |
| Q38039112 | The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy |
| Q35538728 | The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies |
| Q35034370 | The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment |
| Q55117611 | Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment. |
| Q38157750 | Therapeutic gene delivery using bioreducible polymers |
| Q26798116 | Therapeutic potential of chemokine signal inhibition for metastatic breast cancer |
| Q33745632 | Top Notch cancer stem cells by paracrine NF-κB signaling in breast cancer |
| Q37246484 | Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy |
| Q38160740 | Tumor metastasis: moving new biological insights into the clinic |
| Q50073017 | Tumor microenvironment heterogeneity: challenges and opportunities |
| Q37728585 | Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis |
| Q39198945 | Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis |
| Q37950602 | Tumor promotion via injury- and death-induced inflammation |
| Q37028767 | Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance |
| Q84067389 | Tumour immunology: Pro-metastatic T(Reg) cells get RANKed |
| Q26766468 | Tumour progression and metastasis |
| Q34281252 | Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade |
| Q36759374 | Understanding and targeting osteoclastic activity in prostate cancer bone metastases |
| Q38988078 | Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. |
| Q38673589 | When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase |
| Q54975654 | miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. |
| Q37452957 | microRNA-mediated regulation of the tumor microenvironment |
| Q55118190 | α-Tocopheryl Succinate Inhibits Osteolytic Bone Metastasis of Breast Cancer by Suppressing Migration of Cancer Cells and Receptor Activator of Nuclear Factor-κB Ligand Expression of Osteoblasts. |
| Q64279107 | ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity |